We herein present an overview of the upcoming 5th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …

Several editions of the World Health Organization (WHO) classifications of lympho-
hemopoietic neoplasms in 2001, 2008 and 2017 served as the international standard for …

Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory
(R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is …

The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …

Mantle cell lymphoma (MCL) is a phenotypically and genetically heterogeneous malignancy
in which the genetic alterations determining clinical indications are not fully understood …

Palatine tonsils are secondary lymphoid organs (SLOs) representing the first line of
immunological defense against inhaled or ingested pathogens. We generated an atlas of …

PURPOSE The need for an individualized management of indolent clinical forms in mantle
cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment …

Mantle cell lymphoma (MCL) is clinically characterised by its heterogenous behaviour with
courses ranging from indolent cases that do not require therapy for years to highly …